Publications

2023

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
Available here

2021

An interesting read, Nature highlights IgE cancer antibodies as a promising new technology to watch in 2021.
www.nature.com/articles/d41586-021-00191-z

2020

Phase 1 trial of MOv18 IgE, a first-in-class IgE antibody therapy for cancer

James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Gareth J Veal, Christopher Corrigan, Stephen Till, George Nintos, Tim Brier, Ionut G Funingana, Joo Ern Ang, Kam Zaki, Annie Griffin1, Claire Barton, Paul Jones, Sarah Mellor, Susan Brook, Katie Stoddart, Christopher Selkirk,Simon Carroll, Heike Lentfer, Natalie Woodman, Amy Pope, Giulia Pellizzari, Mano Nakamura, KristinaM Ilieva, Atousa Khiabany, Chara Stavraka, Hannah Gould, Jitesh Chauhan, Heather J Bax, Sarah Pinder, Debra H Josephs & Sophia N Karagiannis

The slides presentation by Prof Spicer are available here

2017

Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.

Josephs DH, Bax HJ, Dodev T, Georgouli M, Nakamura M, Pellizzari G, Saul L, Karagiannis P, Cheung A, Herraiz C, Ilieva KM, Correa I, Fittall M, Crescioli S, Gazinska P, Woodman N, Mele S, Chiaruttini G, Gilbert AE, Koers A, Bracher M, Selkirk C, Lentfer H, Barton C, Lever E, Muirhead G, Tsoka S, Canevari S, Figini M, Montes A, Downes N, Dombrowicz D, Corrigan CJ, Beavil AJ, Nestle FO, Jones PS, Gould HJ, Sanz-Moreno V, Blower PJ, Spicer JF,Karagiannis SN.

Cancer Res. 2017 Mar 1;77(5):1127-1141. doi: 10.1158/0008-5472.CAN-16-1829. Epub 2017 Jan 17.
PMID:28096174

2015

Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.

Saul L, Josephs DH, Cutler K, Bradwell A, Karagiannis P, Selkirk C, Gould HJ, Jones P, Spicer JF, Karagiannis SN.
MAbs. 2014 Mar-Apr;6(2):509-22. doi: 10.4161/mabs.27828. Epub 2014 Jan 14.

PMID:24492303

2014

IgE immunotherapy: a novel concept with promise for the treatment of cancer.

Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN.
MAbs. 2014 Jan-Feb;6(1):54-72. doi: 10.4161/mabs.27029. Review.

PMID:24423620

2012

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.

Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, Dodev T, Koers A, Blower PJ, Corrigan C, Beavil AJ, Spicer JF, Nestle FO, Gould HJ.
Cancer Immunol Immunother. 2012 Sep;61(9):1547-64. doi: 10.1007/s00262-011-1162-8. Epub 2011 Dec 3. Review.
PMID:22139135

2009

Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.
Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, Karagiannis SN.

Cancer Immunol Immunother. 2009 Jun;58(6):915-30. doi: 10.1007/s00262-008-0607-1. Epub 2008 Oct 22.

PMID:18941743

2008

Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.

Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ, Dombrowicz D, Balkwill FR, Gould HJ.

Cancer Immunol Immunother. 2008 Feb;57(2):247-63. Epub 2007 Jul 27.

PMID:17657488

2007

IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.

Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, Moore RJ, Dombrowicz DD, Balkwill FR, Gould HJ.

J Immunol. 2007 Sep 1;179(5):2832-43.
PMID:17709497

2003

Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.

Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ.
Eur J Immunol. 2003 Apr;33(4):1030-40.

PMID:12672069

1999

Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma.

Gould HJ, Mackay GA, Karagiannis SN, O’Toole CM, Marsh PJ, Daniel BE, Coney LR, Zurawski VR Jr, Joseph M, Capron M, Gilbert M, Murphy GF, Korngold R.
Eur J Immunol. 1999 Nov;29(11):3527-37.

PMID: 10556807